Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of health-care research products company Affymetrix (Nasdaq: AFFX) shot up as much as 17% in intraday trading on higher-than-average volume.

So what: Affymetrix made a slew of announcements this morning, the most important of which -- from the market's perspective, at least -- was likely the update on fourth-quarter results. The company said that it expects to show $85 million in revenue for the quarter and positive operating and net income on a GAAP basis. The revenue number is roughly in line with Wall Street estimates, while the GAAP earnings look to be above the current GAAP expectations of slightly below breakeven. Current adjusted earnings per share estimates from Wall Street are $0.02.

Now what: Investors can look forward to more detail on the quarterly numbers when Affymetrix reports full results early next month. Since little detail was given on exactly how much profit the company will report, there is still substantial room for investors to be surprised to either the upside or downside. Stepping back to the bigger picture, the company also announced today that it has signed a distribution deal with the Fisher Scientific arm of Thermo Fisher Scientific (NYSE: TMO). The agreement involves Affymetrix's GeneAtlas System, and it's hoped that the partnership will significantly increase Affymetrix's reach in the research markets.

Want to keep up to date on Affymetrix? Add it to your watchlist.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Fool contributor Matt Koppenheffer does not own shares of any of the companies mentioned. You can check out what Matt is keeping an eye on by visiting his CAPS portfolio, or you can follow Matt on Twitter @KoppTheFool or on his RSS feed. The Fool's disclosure policy prefers dividends over a sharp stick in the eye.